Table 2.

Interacting effects of 25(OH)D and SNPs in vitamin D metabolism genes on the 5-year risk of breast cancer: Ratio of HRs and 95% CI [N = 3,334a; 1,810 in subcohort (66 cases) and 1,524 additional cases]

RankSNPLocationGeneMinor allele frequencyb25(OH)D-breast cancer HR in noncarriersRatio of HR (95% CI)cInteraction P
1rs432826212: 48285648VDR0.410.92 (0.68–1.24)0.67 (0.53–0.85)0.0008
2rs1116828712: 48285414VDR0.470.92 (0.64–1.31)0.71 (0.56–0.90)0.004
3rs11791312411: 14900931CYP2R10.020.71 (0.59–0.84)5.96 (1.71–20.8)0.005
4rs423785512: 48287203VDR0.370.83 (0.63–1.10)0.73 (0.58–0.92)0.007
5rs1788398412: 48293716VDR0.320.60 (0.46–0.78)1.34 (1.05–1.71)0.02
6rs451603512: 48299826VDR0.40.56 (0.42–0.76)1.30 (1.04–1.64)0.02
7rs223918212: 48255411VDR0.50.53 (0.37–0.76)1.27 (1.01–1.58)0.04
8rs31323019: 137294030RXRA0.190.65 (0.52–0.81)1.36 (1.01–1.84)0.04
9rs31322969: 137302631RXRA0.340.68 (0.52–0.89)1.28 (1.00–1.65)0.05
10rs31185369: 137308462RXRA0.170.66 (0.53–0.81)1.35 (0.98–1.84)0.06
11rs198996912: 48278010VDR0.40.69 (0.52–0.91)1.25 (0.98–1.60)0.07
12rs350791689: 137280939RXRA0.390.62 (0.47–0.83)1.25 (0.98–1.59)0.07
13rs111029869: 137285503RXRA0.180.66 (0.53–0.81)1.32 (0.97–1.78)0.07
14rs712978111: 14912417CYP2R10.080.70 (0.58–0.85)1.44 (0.93–2.23)0.10
15rs1279471411: 14913575CYP2R10.420.98 (0.74–1.30)0.81 (0.62–1.06)0.12
16rs88644112: 48262964VDR0.210.62 (0.50–0.77)1.25 (0.94–1.65)0.12
17rs285356412: 48278487VDR0.370.69 (0.53–0.91)1.20 (0.95–1.53)0.13
18rs222857212: 48272840VDR0.020.76 (0.64–0.90)0.52 (0.22–1.22)0.13
19rs796715212: 48244184VDR0.460.59 (0.42–0.82)1.19 (0.95–1.51)0.14
20rs223917912: 48257766VDR0.420.76 (0.56–1.04)0.84 (0.67–1.06)0.14
21rs49173549: 137237661RXRA0.310.64 (0.50–0.82)1.20 (0.93–1.55)0.16
22rs11555634: 72643488GC0.270.65 (0.52–0.82)1.22 (0.92–1.64)0.17
23rs18053439: 137328286RXRA0.380.66 (0.50–0.87)1.18 (0.93–1.49)0.18
24rs45884: 72618323GC0.270.64 (0.51–0.80)1.22 (0.91–1.65)0.19
25rs218187420: 52784478CYP24A10.250.66 (0.52–0.85)1.18 (0.91–1.54)0.21
26rs1157414312: 48234917VDR0.110.78 (0.64–0.94)0.80 (0.55–1.16)0.24
27rs223918612: 48269410VDR0.180.68 (0.55–0.85)1.19 (0.89–1.60)0.24
28rs224809812: 48253356VDR0.480.62 (0.44–0.88)1.15 (0.91–1.45)0.24
29rs229624120: 52786219CYP24A10.480.84 (0.62–1.15)0.87 (0.69–1.10)0.24
30rs276293420: 52771261CYP24A10.180.68 (0.56–0.85)1.19 (0.89–1.61)0.25
31rs972912: 48236623VDR0.460.61 (0.44–0.85)1.14 (0.90–1.43)0.28
32rs75734312: 48239675VDR0.120.77 (0.63–0.94)0.82 (0.58–1.17)0.28
33rs222857012: 48272895VDR0.360.70 (0.53–0.92)0.89 (0.71–1.11)0.30
34rs223813612: 48277713VDR0.240.79 (0.62–1.00)0.87 (0.66–1.14)0.31
35rs1699911620: 52777467CYP24A10.140.77 (0.63–0.94)0.85 (0.61–1.17)0.31
36rs3587357920: 52788190CYP24A10.030.75 (0.63–0.90)0.68 (0.31–1.47)0.33
37rs1089819311: 71197083NADSYN10.170.69 (0.56–0.85)1.17 (0.85–1.61)0.35
38rs104453511: 71145778DHCR70.080.70 (0.58–0.84)1.25 (0.78–1.99)0.35
39rs480995820: 52782438CYP24A10.160.78 (0.64–0.96)0.86 (0.62–1.19)0.37
40rs356036359: 137323202RXRA0.030.75 (0.63–0.90)0.73 (0.37–1.45)0.37
41rs797512812: 48245828VDR0.390.76 (0.57–1.02)0.90 (0.71–1.14)0.38
42rs381954512: 48265006VDR0.370.77 (0.58–1.02)0.90 (0.71–1.14)0.39
43rs223813512: 48278190VDR0.250.78 (0.62–0.98)0.88 (0.67–1.17)0.39
44rs6174968920: 52790005CYP24A10.020.75 (0.63–0.90)0.73 (0.33–1.58)0.42
45rs157066920: 52774427CYP24A10.370.85 (0.65–1.11)0.91 (0.72–1.16)0.45
46rs1116827512: 48272275VDR0.230.75 (0.60–0.95)0.90 (0.68–1.18)0.45
47rs10455709: 137332311RXRA0.160.71 (0.58–0.88)1.13 (0.83–1.53)0.45
48rs225421012: 48273714VDR0.360.73 (0.56–0.96)1.10 (0.86–1.40)0.46
49rs13528444: 72647749GC0.120.77 (0.63–0.94)0.89 (0.64–1.24)0.48
50rs1271799112: 48259126VDR0.370.69 (0.52–0.91)1.08 (0.85–1.37)0.54
51rs73123612: 48238757VDR0.390.76 (0.57–1.01)0.93 (0.74–1.17)0.54
52rs111856609: 137259992RXRA0.250.70 (0.56–0.88)1.09 (0.83–1.43)0.56
53rs7051204: 72614140GC0.420.66 (0.50–0.88)1.08 (0.84–1.38)0.57
54rs1278587811: 71167449NADSYN10.30.71 (0.56–0.89)1.08 (0.83–1.41)0.57
55rs65379989: 137292505RXRA0.030.73 (0.61–0.87)1.22 (0.60–2.50)0.58
56rs2220204: 72636272GC0.190.80 (0.65–0.99)0.92 (0.67–1.26)0.59
57rs154033912: 48257326VDR0.360.67 (0.51–0.89)1.06 (0.84–1.34)0.61
58rs678162429: 137268441RXRA0.240.71 (0.57–0.88)1.07 (0.81–1.42)0.62
59rs224835920: 52791518CYP24A10.410.62 (0.46–0.84)1.05 (0.84–1.32)0.68
60rs70380189: 137309959RXRA0.140.74 (0.60–0.90)1.07 (0.77–1.48)0.68
61rs37333594: 72649774GC0.090.75 (0.62–0.90)0.92 (0.58–1.44)0.71
62rs223918012: 48256046VDR0.120.71 (0.59–0.87)1.07 (0.75–1.51)0.72
63rs14330442011: 71144815DHCR70.030.73 (0.61–0.88)1.13 (0.56–2.28)0.73
64rs224846120: 52792202CYP24A10.390.63 (0.47–0.84)1.04 (0.83–1.30)0.76
65rs2220094: 72631735GC0.020.74 (0.62–0.88)0.82 (0.21–3.22)0.78
66rs43642284: 72623347GC0.10.75 (0.62–0.90)0.95 (0.63–1.41)0.78
67rs1087701212: 58162085CYP27B10.30.68 (0.52–0.88)0.97 (0.76–1.23)0.79
68rs228334212: 48255859VDR0.140.75 (0.61–0.92)0.96 (0.69–1.33)0.81
69rs713653412: 48294626VDR0.250.73 (0.58–0.93)1.03 (0.79–1.35)0.82
70rs1190735020: 52770439CYP24A10.040.73 (0.61–0.87)1.07 (0.57–2.02)0.82
71rs1157402612: 48288246VDR0.110.74 (0.61–0.90)1.04 (0.70–1.55)0.85
72rs343121369: 137269456RXRA0.40.70 (0.52–0.95)1.02 (0.81–1.29)0.86
73rs1074165711: 14914878CYP2R10.370.71 (0.52–0.97)1.02 (0.81–1.29)0.86
74rs96159: 137331525RXRA0.040.73 (0.61–0.88)0.96 (0.50–1.82)0.90
75rs229623920: 52775528CYP24A10.240.79 (0.63–0.98)0.99 (0.75–1.30)0.92
76rs1116826712: 48251542VDR0.090.72 (0.60–0.87)1.02 (0.68–1.53)0.92
77rs378290512: 48266167VDR0.320.72 (0.55–0.94)0.99 (0.78–1.26)0.93
78rs602298720: 52770596CYP24A10.290.75 (0.58–0.97)1.01 (0.78–1.31)0.94
79rs1087569312: 48269650VDR0.330.75 (0.57–0.98)0.99 (0.78–1.26)0.94
80rs92765020: 52772741CYP24A10.460.73 (0.53–1.00)1.00 (0.80–1.26)0.97
81rs780777369: 137257165RXRA0.050.74 (0.62–0.88)1.00 (0.57–1.73)0.99
82rs210730112: 48255570VDR0.270.72 (0.56–0.91)1.00 (0.78–1.29)0.99
  • aAfter excluding those with missing covariate information.

  • bAmong subcohort members.

  • cThe minor allele is the index allele, so a value >1.00 indicates that 25(OH)D has a stronger protective association with breast cancer among those with no copies of the minor allele than those with 1 or 2, assuming a log-additive genetic model. Similarly, an RHR <1.00 indicates that 25(OH)D has a stronger inverse association with breast cancer among those 1 or 2 copies of the minor allele than those none.